Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 7Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Rectal Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Gemcitabine 17pembrolizumab 16Cisplatin 14enfortumab vedotin 7avelumab 7Nivolumab 6Docetaxel 6atezolizumab 5Paclitaxel 5Cystectomy 5sacituzumab govitecan 4durvalumab 4Mitomycin 4Cystoscopy 4Carboplatin 4vofatamab 3tremelimumab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3vinflunine 2tisotumab vedotin 2poly ICLC 2cemiplimab 2aldesleukin 2Transurethral Resection of Bladder 2Radiotherapy, Intensity-Modulated 2Ipilimumab 2Interleukin-2 2Immunoglobulin G 2Clinical Trials, Phase II as Topic 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Urinary Bladder Neoplasms × BCG Vaccine × Clear all
NCT02792192 2021-10-28

Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants

Hoffmann-La Roche

Phase 1/2 Terminated
24 enrolled 18 charts
Genitourinary

Urinary Bladder Neoplasms

NCT02010203 2020-02-17

A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT

Heat Biologics

Phase 1/2 Terminated
104 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡